Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers
Merger Means Billions for Biotechnology?
February 16, 2011 By Leave a Comment
In March 2009, we asked the question “Where Might Genentech Investors Redeploy $47 Billion?” in response to the news that Roche Holding AG (RHHBY.PK) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in cash. We hypothesized that investors seeking biotechnology companies of comparable size and liquidity [...]
Where Might Genentech Investors Redeploy $47 Billion?
March 15, 2009 By Leave a Comment
Following a spate of high profile clinical setbacks and regulatory delays that sent the sector into a tailspin during the final week of February 2009 (see prior column), investors shrugged off further disappointing clinical news as merger and acquisition activity helped biotechnology stocks stage a partial recovery last week. The NASDAQ Biotech Index (NBI) gained [...]
2009: Positive Perspectives for Biotechnology
January 7, 2009 By 4 Comments
After a brief bout of euphoria during the early portion of the decade, the biotechnology industry, as measured by the Amex Biotech Index (BTK), was shunned by investors for the better part of the 1990’s. The BTK, which was established with a benchmark value of 200 on October 18, 1991, declined by 50% to nearly [...]
Follow MD Becker Partners